Emerging Trends and Competitive Landscape in the Gemigliptin Market
The Gemigliptin Market is witnessing significant growth and innovation driven by the rising prevalence of diabetes worldwide. Gemigliptin, a novel dipeptidyl peptidase-4 (DPP-4) inhibitor, is gaining traction as an effective treatment option for type 2 diabetes mellitus.
The global gemigliptin market size was valued at US$ 1.79 Bn in 2024 and is expected to reach US$ 2.59 Bn by 2031, grow at a compound annual growth rate CAGR of 5.4% from 2024 to 2031.